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Precis: We show that combining mass spectrometry-based steroid profiling and machine learning-based 
data analysis is a promising tool for post-operative recurrence detection in adrenocortical carcinoma.   
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 4 
Abstract  
Context: Urine steroid metabolomics, combining mass spectrometry-based steroid profiling and machine 
learning, has been described as a novel diagnostic tool for detection of adrenocortical carcinoma (ACC).  
Objective, Design, Setting:  This proof-of-concept study evaluated the performance of urine steroid 
metabolomics as a tool for post-operative recurrence detection after microscopically complete (R0) 
resection of ACC.  
Patients and Methods: 135 patients from 14 clinical centers provided post-operative urine samples, 
which were analyzed by gas chromatography-mass spectrometry. We assessed the utility of these urine 
steroid profiles in detecting ACC recurrence, either when interpreted by expert clinicians, or when 
analyzed by Random Forest, a machine learning-based classifier. Radiological recurrence detection 
served as the reference standard. 
Results: Imaging detected recurrent disease in 42 of 135 patients; 32 had provided pre- and post-
recurrence urine samples. 39 patients remained disease-free for 3 years. The   i e “  e  i   i  e   i  ” 
at recurrence resembled that observed before R0 resection in the majority of cases.  Review of 
longitudinally collected urine steroid profiles by three blinded experts detected recurrence by the time of 
radiological diagnosis in 50-72% of cases, improving to 69-92%, if a pre-operative urine steroid result 
was available. Recurrence detection by steroid profiling preceded detection by imaging by more than 2 
months in 22-39% of patients. Specificities varied considerably, ranging from 61 to 97%.  The 
computational classifier detected ACC recurrence with superior accuracy (sensitivity=specificity=81%).   
Conclusion: Urine steroid metabolomics is a promising tool for post-operative recurrence detection in 
ACC; availability of a pre-operative urine considerably improves the ability to detect ACC recurrence.   
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 5 
Introduction 
Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy (1,2). Disease recurrence 
rates are high, even in patients with microscopically complete (R0) resection (3,4). Therefore, vigilant 
surveillance of all operated patients by regular cross-sectional imaging for several years is essential to 
facilitate early intervention in case of recurrence (5-7). Although the optimal surveillance protocol has yet 
to be established, a common approach involves three-monthly CT scans (thorax, abdomen, pelvis) in the 
first two post-operative years, six-monthly CT scans in the next three years and, thereafter, annual scans 
until 10 years post-operatively (8). This is associated with considerable costs, repeated radiation exposure 
and frequent diagnostic ambiguity in early stages of recurrent/metastatic disease (9). Early detection of 
disease recurrence is important, as it may allow radical revision surgery in cases of limited metastatic 
disease volume, or timely initiation of cytotoxic chemotherapy, potentially improving survival (5,7,10-
13). The number of metastatic sites at diagnosis of recurrent disease, as well as time from surgery to 
detection of recurrence, have been shown to be independent prognostic factors (10,14). 
Most ACCs are biochemically active, typically presenting a steroidogenic pattern dominated by 
steroid precursor metabolites rather than end products of steroidogenesis (15). This pattern has been 
attributed to the relative dedifferentiation of malignant cells (15,16). Most of these steroid precursors, 
which represent intermediate steps along the three major adrenocortical steroid biosynthetic pathways, are 
not measured by routine clinical biochemistry. Analysis of 24-h urine collections by gas chromatography-
mass spectrometry (GC-MS), however, can identify and quantify the metabolites of the large majority of 
adrenal-derived steroids, providing a truly comprehensive steroid profiling tool (15). This allows the 
detection of minute changes in steroidogenesis and the illumination of all intermediate steps that tend to 
be perturbed in the setting of adrenocortical malignancy. Recent retrospective studies revealed the 
capacity of urinary steroid profiling to distinguish ACC from benign adrenal tumors. In 2011, our group 
analyzed steroid metabolite profiles in 24-h collections from 102 patients with benign adrenocortical 
adenomas and 56 patients with ACC by GC-MS (15). Machine learning-based analysis of the steroid data 
identified a distinct malignant   e  i  ‘ i  e   i  ’ for ACC and could differentiate benign from 
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 6 
malignant adrenal tumors with a sensitivity and specificity of 90% (15). Using GC-MS, 95% of ACCs 
showed evidence of steroid excess, while routine biochemistry only indicated steroid excess in 73% (15). 
Two subsequent retrospective studies also employing GC-MS produced similar results, albeit in smaller 
cohorts and without the use of machine learning analysis (16,17).  
In this study, we evaluated the diagnostic performance of urine steroid metabolomics, the 
combination of mass spectrometry-based steroid profiling and data analysis by machine learning-based 
algorithms, in the post-operative surveillance of ACC patients following microscopically complete (R0) 
tumor resection. We assessed the performance of this approach in the detection of disease recurrence, also 
comparing direct interpretation of steroid profiles by clinical experts to fully automated, machine 
learning-based analysis of the steroid metabolome. 
Methods 
Patients and clinical protocol 
Serial post-operative 24-h urine samples were collected from patients with histologically 
confirmed ACC, who had undergone microscopically complete (R0) tumor resection in 14 clinical 
specialist referral centers participating in the European Network for the Study of Adrenal Tumors 
(ENS@T; www.ensat.org), with approval of local ethical review boards and after obtaining written 
informed patient consent. Participating countries included the UK (Birmingham), Germany (Würzburg, 
Munich, Berlin), France (Paris), Italy (Florence, Turin), Greece (Athens), the Republic of Ireland (Dublin, 
Galway), Poland (Warsaw), Croatia (Zagreb), and Portugal (Coimbra, Lisbon). Urine samples were 
collected between 2007 and 2016. Inclusion criteria were defined as a) histologically confirmed diagnosis 
of ACC, b) complete (R0) tumor resection and c) provision of at least one post-operative 24-h urine 
sample when disease-free, i.e. before any radiological evidence of disease recurrence (as assessed by CT 
thorax, abdomen and pelvis), and within two years from surgery.  Participating centers were prompted to 
provide urine samples every three months, but actual frequency of provided samples did not constitute an 
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 7 
exclusion criterion as long as at least one post-operative sample had been provided at a time with no 
evidence of disease recurrence on surveillance imaging. 
ACC recurrence had to be confirmed by one of the following: a) emergence of new lesions on 
cross-sectional imaging (CT, MRI), which either enlarge on follow-up scans, or regress in response to 
systemic antitumor therapy; b) emergence of enhancing lesions on PET or PET-CT scans; or c) 
histological evidence of recurrent/metastatic ACC from percutaneous biopsy or revision surgery.  
Biochemical analysis 
Measurement of 24-h urinary steroid metabolite excretion was carried out by gas 
chromatography-mass spectrometry (GC-MS), as described in detail previously (15). In brief, free and 
conjugated steroids were extracted from 1 ml urine by solid-phase extraction. Steroid conjugates were 
enzymatically hydrolyzed, re-extracted, and chemically derivatized to form methyloxime trimethyl silyl 
ethers. GC-MS was carried out on an Agilent 5975 instrument operating in selected-ion-monitoring (SIM) 
mode to achieve sensitive and specific detection and quantification of 19 selected steroid metabolites 
(Table 1) c    i i   ei h      he  i e   e i   ly  e c i e  “ ali  a     e  i   i  e   i  ”  e a  li e  
indicative of ACC (15). We did not include glucocorticoid metabolites as these are uninterpretable in 
mitotane-treated ACC patients, who all receive high-dose glucocorticoid replacement while also being 
subject to the strong induction of the cortisol-metabolizing enzyme CYP3A4 by mitotane (18). 
Clinical expert review of steroid profiles 
Three clinical experts with extensive experience in adrenal disease (I.B., M.O.R., W.A.) were 
provided with longitudinally collected post-operative urinary steroid profiles from patients who either a) 
developed disease recurrence (=“recurrence cohort”) or b) remained recurrence-free over a follow-up 
period of at least three years, which we considered our “recurrence negative” cohort, as the chances of 
ACC recurrence past this time-point are low (19). P   i i      a  lea     e  a  le a  a ‘ i ea e-  ee’   a e 
was an essential inclusion criterion for this study; therefore, all included recurred patients had provided at 
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 8 
least two post-operative urine samples (one pre- and one post-recurrence). Similarly, we only included 
patients from the “recurrence-free” cohort who had provided at least two post-operative urine samples for 
this study part. Pre-operative steroid profiles were provided when available.  
The three assessors were blinded to clinical and radiological information other than basic patient 
demographics (age, sex) and were only provided with a previously established steroid metabolite 
reference range derived from a healthy adult control cohort (age range 20-81 years; 77 women, 54 men). 
The clinical experts were asked t  i e  i y  he  i      i e i  ica i e    a  ec   e ce (     a e “   
 ec   e ce” i   a ie     ha   hey c   i e e  a     -recurred), taking into account differences of the 
  e  i      ile      h  e    e  e  i  heal hy c     l  a    he   e i   ly    e  e  “ ali  a     e  i  
 i  e   i  ” i   a ie     i h a   i a y A         i   i   (15).  
Recurrence detection by the clinical experts was considered successful only if based on 
interpretation of the steroid profile in a urine sample collected before or at the time of the first 
radiological detection of recurrent disease. This means that late biochemical detection in relation to 
imaging did not count as true positive for the purposes of sensitivity calculations. 
Machine learning-based data analysis   
Supervised machine learning was used to create an approach for automatic separation of recurrent 
from non-recurrent patients (20). The machine learning algorithm was developed by presenting the results 
of the 19 steroid markers measured by GC-MS in a given 24-h urine, and the corresponding output, i.e. a 
“yes” or “no” answer to the question whether or not an ACC recurrence had been radiologically detected 
at the time of urine collection. F     he e “  ai i  ” e a  le ,  he al   i h  lea  ed to generalize by 
finding patterns in the steroid data and use them to provide an output answer when the output is not 
known. 
We used machine learning to approach two separate two-class classification problems. First, we 
considered the differentiation of all 215 urine samples collected in the 39 non-recurred patients from all 
76 urine samples collected post-recurrence in the 32 recurred patients. Second, to test the ability of our 
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 9 
approach for very early detection, we aimed to differentiate all non-recurred samples against the first 
urine sample collected in each recurrent patient at the time of first radiological detection of ACC 
recurrence (35 samples, as three of 32 patients had two recurrences). 
Random Forests were used as machine learning classifier (21,22). The Random Forest is a 
classification framework based on the concept of decision trees. It builds a forest of many decision trees 
in order to create a strong classifier that is resistant to noise and overtraining. Another favorable property 
of Random Forests is that they give insight into the importance of features, which we exploited to inspect 
the contribution and relevance of each steroid metabolite in the classification problem. For all 
experiments training the Random Forest prediction models and validating them, we used Matlab 2015a, 
specifically, the TreeBagger class of Matlab (included in the Statistics and Machine Learning Toolbox) 
(Matlab documentation, 2018). In order to estimate predictor importance, the parameter that controls 
computation of predict   i     a ce  a   e     ‘  ’ ( hi   a a e e  i  calle  ‘    a i  ’ i  Ma la  
2015a). The number of decision trees used to obtain the results was 128, which provided optimal trade-off 
between speed and performance. Ten-fold cross-validation was used to estimate the classifier's predictive 
quality. In order to account for the differences in the number of samples between the healthy and the 
recurrence classes, the validation procedure was repeated 50 times for randomized splits of the data. In 
each run, the healthy class was randomly sub-sampled to make sure that both classes had an equal number 
of samples. 
Statistical analysis 
Data analysis and graphic representation was completed using GraphPad Prism Software Version 
8. Data are summarized as median (interquartile range, IQR) values unless otherwise stated. Sensitivities 
and specificities are accompanied by 95% confidence intervals (95%CI), derived using the Wilson/Brown 
method (23,24).   
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 10 
Results 
Patient characteristics 
We recruited 135 patients (50 men, 85 women) who had undergone complete (R0) resection of a 
histologically confirmed ACC and provided at least one 24-h urine sample while considered disease-free 
according to their most recent clinical and radiological assessment and no later than 2 years post-
operatively (Fig. 1). Median age at diagnosis was 49 years (range 18-80 years).  
During a median follow-up period of 32 months (interquartile range (IQR) 15-48 months), 42 of 
135 patients (31 %) developed disease recurrence; of these, 10 had to be excluded from the analysis as 
they had not provided 24-h urines after the detection of recurrence. Of the cohort of patients who 
remained disease-free post-operatively, 39 were clinically and radiologically followed for more than 3 
years; as ACC recurrence presenting beyond that time frame is rare (19), we defined those 39 patients as 
the “recurrence-free” cohort for the purposes of this study. Relevant clinical details of both cohorts are 
summarized in Table 2.   The remaining 54 patients without radiological evidence of recurrence but post-
operative follow-up <3 years were excluded from further analysis, as they were still at high risk of 
potentially harboring minimal recurrent disease which had yet to manifest radiologically.  
The 39  a ie        he “ ec   e ce-  ee” c h    provided a median of 4 (range 1-24) post-
operative 24-h urine samples.      he “ ec   e ce” c h   , the patients collected a median of 5 (range 2-
35) post-operative 24-h urine samples; 13 of the 32 patients had also collected a pre-operative 24-h urine 
sample, facilitating the comparison of steroid profiles observed at diagnosis of the primary tumor and at 
detection of ACC recurrence. All samples provided by the recurred patients are depicted in Fig. 2A, 
plotted against time after surgery. Single-organ involvement at recurrence detection was diagnosed in 26 
of the 32 recurred patients; the remaining six had disease affecting more than one organ (Table 2). We 
classified 15 of the 32 recurrences a  ‘hi h   l  e’ a   he  i e     he first abnormal imaging, defined as 
at least one solid-organ lesion 1 cm, and 12 a  ‘l     l  e’; five were indeterminate due to incomplete 
imaging information.  
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Longitudinal urine steroid profiling   
We hypothesized that the development of radiologically detectable recurrent or metastatic disease 
would be heralded by an increase in one or more adrenal steroid metabolites excreted in 24-h urine. Such 
changes were indeed observed; indicative example cases are shown in heat-map format in Fig. 2B.  
An important question here  a   he he   he “ ali  a     e  i   i  e   i  ”    e  e  a   a eli e, 
i.e. in the pre-operative urine at the time of first diagnosis of ACC, represents an inherent characteristic of 
the individual ACC that is largely preserved upon disease recurrence. We found that this was indeed the 
case, with re-emergence of steroid metabolites at recurrence mostly identical to those found increased at 
baseline in the vast majority of patients (Fig. 3A). The overall six most increased steroids comprised the 
11-deoxycortisol metabolite THS, the 11-deoxycorticosterone metabolite THDOC, the pregnenolone and 
17-hydroxypregnenolone metabolites 5-PD and 5-PT, as well as the progesterone and 17-
hydroxyprogesterone metabolites PD and PT  (Fig. 3B). The magnitude of steroid marker elevation, 
however, was substantially smaller upon disease recurrence than in primary ACCs (Table 3), as expected 
in view of the major differences in disease volume between primary tumor  and ACC recurrence (median 
maximum diameter 92 vs. 11 mm, respectively; Table 2). 
Expert clinician assessment of steroid profiling results 
To evaluate the extent to which incipient steroid profile changes can facilitate diagnosis of 
recurrent disease, we asked three expert endocrinologists to retrospectively review longitudinal series of 
urinary steroid profiles individually derived from   he ‘ ec   e ce’ a   ‘ ec   e ce-free’  a ie   c h    .  
The three expert clinicians were able to correctly identify recurrent disease by the time of the first post-
recurrence sample (defined by reference to the first abnormal surveillance scan) with sensitivities of 66% 
(95% CI 48-80%), 53% (95% CI 36-69%) and 75% (95% CI 58-87%)  (clinicians 1, 2 and 3, 
respectively). This improved substantially for the subgroup of patients who had provided pre-operative 
urine samples (n=13) to 85% (95%CI 58-97%), 69% (95%CI 42-87%) and 92% (95%CI 67-100%), 
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 12 
respectively (Fig. 4A). Of note, eight of the 13 assessed recurrences in these patients were unanimously 
detected by all three reviewing clinicians. Absence of a pre-operative sample curtailed diagnostic 
sensitivities to 53% (95%CI 32-73%), 42% (95%CI 23-64%) and 63% (95%CI 41-81%).  
The diagnostic performance of the steroid profile review was not altered by adjuvant mitotane 
treatment (Fig. 4B). Whether the tumor was found to be hormonally active or not at baseline (on clinical 
biochemistry) also did not appear to affect the diagnostic performance of the urine steroid metabolome on 
recurrence (data not shown).  
The proportion of non-recurred patients in whom recurrences were  incorrectly detected by 
reviewing clinicians  varied considerably across the assessors (false positive rates 23% [95%CI 11-39%],  
3% [95%CI 0-16%] and 39% [95%CI 24-56%] for clinicians 1, 2 and 3, respectively; Fig. 4C). The effect 
of the availability of a pre-operative urine sample on the specificity of detection could not be 
meaningfully assessed as only five non-recurred patients had provided a pre-operative sample.  
Tumor volume at the time of first abnormal surveillance imaging was a second clinical factor, 
which showed a tendency towards affecting clinician ability to detect recurrence (high-volume 
recurrence: sensitivities 67% [95% CI 42-85%], 53% [95% CI 30-75%] and 87% [95%CI 62-98%]; low-
volume recurrence: 50% [95% CI 25-75%], 42% [95%CI 19-68%] and 58% [95%CI 32-81%] for 
clinicians 1-3, respectively).  
Of note, a considerable proportion of correct recurrence detections (ranging from 22-39% for the 
three experts) were made based on urine collections that pre-dated the first radiological evidence of 
recurrence by more than 2 months (Fig. 4D). Only a small number of recurrences were detected later by 
urine steroid profile interpretation than radiological detection. If late detections were accepted as positive, 
the overall sensitivities of the clinicians would improve to 75% (95% CI  58-87%), 56% (95% CI 39-
72%), and 81% (95% CI 65-91%) for clinicians 1-3, respectively. 
Computational analysis of steroid data 
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 13 
Machine learning-based analysis of the urine steroid profile data by Random Forests were able to 
distinguish post-recurrence urine samples (n=76) provided by the 32 recurred patients from post-operative 
urine samples (n=215) provided by the 39 non-recurred patients with high accuracy (85%; Area under the 
ROC curve (AUROC) 0.89, 95%CI 0.86-0.91; sensitivity=specificity=81%) (Fig. 5A).   
When considering only the first post-recurrence urine sample from each patient in the 
“ ec   e ce” c h   , the accuracy of Random Forest classification was lower at 75% (AUROC 0.80, 95% 
CI 0.75-0.85) (Fig. 5A), with the urine of 18 of 32 patients correctly classified as indicative of ACC 
recurrence (sensitivity 56%, CI 39-72%); in 6 of these patients, recurrence was also detected in samples 
that preceded the first abnormal imaging. Applying the same diagnostic cut-off, 79% of samples provided 
 y  a ie    i   he ‘   - ec   e ’ c h     e e correctly identified as non-recurred (false positive rate 21% 
[95% CI 16-27%] ).  
High-volume recurrences were more likely to be detected by the Random Forest classifier 
(sensitivity 60% (95% CI 36-80%) vs. 42% (95% CI 19-68%) in low-volume recurrences). However, 
detection was not affected by mitotane treatment (sensitivity 55% [95% CI 34-74%] in mitotane-treated 
patients vs.  58% [95% CI 32-81%] in patients not treated with mitotane). Interestingly, in 11 of 18 
successfully diagnosed recurred patients, recurrence had also been unanimously detected by all three 
assessing clinicians, and in 16 of 18 by at least two different clinicians.  
The machine learning analysis determined the 11-deoxycortisol metabolite tetrahydro-11-
deoxycortisol (THS) as the single most important steroid metabolite in differentiating post-recurrence 
urine samples from samples provided by non-recurred patients, followed by the mineralocorticoid 
precursor metabolite tetrahydrocorticosterone (THDOC), the pregnenolone metabolite pregnenediol (5-
PD) and the androgen metabolite etiocholanolone (Et) (Fig. 5B).   
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Discussion 
In this study, we explored the utility of urinary steroid profiling as a novel diagnostic tool for 
recurrence detection in patients with microscopically complete (R0) resection of ACC. Results show that 
analysis of the steroid profiling data by a machine learning-based algorithm represents a highly promising 
non-invasive and radiation-free tool. Once validated prospectively, this would be a useful addition to the 
current imaging-focused follow-up protocols, expediting scans in patients with suspicious biochemistry 
and informing discussions in cases with ambiguous imaging results.  
Urinary steroid profiling in conjunction with machine learning-based data analysis, also termed 
urine steroid metabolomics, has already yielded highly promising results in several retrospective studies 
in patients with primary adrenal masses, where it was employed to differentiate ACCs from benign 
adrenal tumors (15,16). In the distinct clinical setting of post-operative patient surveillance after resection 
of ACC, the use of urine steroid profiling has only been reported in a few cases (25,26), but has never 
been systematically investigated.  
In the present study, we studied 135 adult patients with microscopically complete R0 resection of 
ACC recruited from 14 centers associated with the European Network for the Study of Adrenal Tumors 
(ENSAT). Of the 81 patients who completed three years of post-operative surveillance, 42 (52%) 
recurred, a rate that is similar to previous retrospective studies (19,27), which suggests that our patient 
cohort is representative of ACC patients routinely seen in clinical practice. 
An important finding of our study is that there were substantial similarities between the steroid 
profiles of recurrent ACCs and their respective steroid profiles collected pre-operatively, with the primary 
tumor in situ. Indeed, half of all recu  e   A     ha e           i e     hei  ‘     ’      ele a e    e  i  
 e a  li e   i h  hei    i a y            i i . M        he ‘ ali  a     e  i   i  a  e  ’  ha   e e 
identified in our 2011 study on primary adrenal tumors (15) were also highly relevant in the context of 
recurrent disease, comprising the ‘     ’ increased metabolites detected in urines collected from patients 
with ACC recurrences. Consequently, expert clinicians had improved ability to detect recurrence if a pre-
operative urine steroid profile was available. This emphasizes the importance of pre-operative, baseline 
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sample collection to facilitate personalized management in patients with ACC, a rare cancer in which 
baseline tissue and blood collection is increasingly becoming routine to support individualized diagnosis 
and therapy (28).  
We assessed the diagnostic potential of urinary steroid profiling as a recurrence surveillance tool 
using two approaches: a) a  ‘e  e    e ie ’ a    ach a   b) automatic recurrence detection by 
computational analysis of steroid data using a machine learning-based algorithm. On retrospective, 
blinded assessment of serial 24-h urine collections, clinicians were able to detect recurrence by the time 
of its first radiological manifestation with high sensitivity in cases where a pre-operative urine sample 
was available. In patients who were only able to contribute post-operative urine samples, the ability of 
clinicians to detect recurrence was substantially lower.  
Adjuvant mitotane did not compromise the diagnostic performance of reviewing clinicians, 
 e  i e  he     ’   ell   c  e  e  a ili y    i hi i    e  i   e e i  (18). Mitotane interferes with 
adrenal steroidogenesis in a number of ways, including a) overall suppression of steroidogenesis resulting 
in lower excretion values for all steroid metabolites, b) increased glucocorticoid breakdown by induction 
of CYP3A4, necessitating high-   e hy   c   i   e  e lace e  ; a   c) 5α-reductase inhibition, leading 
to a decrease in 5α-reduced steroids (18). Although mitotane appeared to blunt the magnitude of the 
increases in ACC-specific steroid biomarkers in recurred patients, it also suppressed the random sample-
to-sample variability, which can be diagnostically helpful. We systematically excluded glucocorticoid 
metabolites from the steroid analysis, as these would be compromised both by mitotane-induced changes 
in glucocorticoid metabolism and exogenous hydrocortisone replacement. 
We applied a machine learning-based approach to the urinary steroid profiling data to detect 
recurrent ACC in an automated and defined fashion. The biochemical complexity of steroidogenesis with 
multiple substrates, products and pathways, in combination with the small underlying disease volumes in 
the setting of recurrent malignancy, render individual biomarkers diagnostically insufficient. Machine 
learning-based approaches are ideally suited to systematically evaluate the wealth of data provided by 
multi-steroid profiling in an objective and reproducible fashion, as already demonstrated in the 
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differential diagnosis of adrenal incidentalomas (15). Our classifier could distinguish recurred samples 
from samples provided by non-recurred patients with considerable accuracy. THS was the most important 
indicator of malignancy, reflecting the pattern of inefficient steroidogenesis in ACC that emerged in 
previous studies on detection of ACC in patients with adrenal masses (15,17,29). Indeed, all but one of 
the six steroids that were identified by Random Forest as most differentiating between recurrence and 
non-recurrence are contained in the   e i   ly  e c i e  “ ali  a     e  i   i  e   i  ” i  A   ( 5). It 
should be noted that, unlike assessing clinicians, the computational classifier did not take into account the 
dynamic longitudinal changes in steroid metabolites in individual patients but judged every sample on its 
own. 
To our knowledge, this is the first study systematically exploring the diagnostic potential of urine 
steroid profiling in the post-operative monitoring of ACC patients. Strengths of our study include the 
large cohort size and the application of computational analysis to meet the demands of the multi-variable 
GC-MS steroid datasets. The limitations of our work pertain to the paucity of pre-operative samples in the 
majority of patients, the variable frequency of post-operative sample collections and the fact that the 
machine learning classifier has not been validated on an additional dataset. We also did not systematically 
compare the results of routine biochemical analysis of serum steroids to the 24-h urine analysis by GC-
MS; however, we previously demonstrated that routine serum biochemistry only identified abnormalities 
in 73% of ACC patients (N=47), while urine steroid metabolomics by GC-MS found abnormalities in 
95% (15). 
On this background, and despite the generally small disease volume in the recurred patients, in 
comparison to patients presenting with a large primary tumors (15), our approach yielded very promising 
diagnostic results. Our data indicate that availability of a pre-operative urine and, thus, of the pre-
  e a i e “  e  i   i  e   i  ” c   i e a ly i     e   he li elih        ec   e ce  e ec i   a  , 
therefore, the preservation of a pre-operative 24-h urine sample should be routinely considered, in 
addition to preservation of serum, plasma and tissue, to facilitate precision medicine.  
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In conclusion, we demonstrated that urine steroid metabolomics, i.e. the combination of mass 
spectrometry-based steroid profiling with machine learning-based steroid data analysis, is superior to 
interpretation of steroid profile results by individual experts. Following potential further refinement of 
this algorithm, this diagnostic approach should be taken forward to be assessed against radiological 
disease detection in a prospective test validation study with systematic collection of pre- and post-
operative urines in defined intervals. This will also allow for systematic comparison of serum and 24-h 
urine steroid profiles and ideally utilize high-throughput technology, such as liquid chromatography-
tandem mass spectrometry or also, as recently published (30), high resolution accurate mass (HRAM) 
mass spectrometry, both assays highly suitable for rollout of urine steroid metabolomics into the routine 
clinical context.  
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Figure Legends 
Fig. 1: Study recruitment flow chart.  
Fig. 2: Panel A, All longitudinal urine samples collected from patients who developed disease 
recurrence, plotted against time from surgery. Blue dots represent post-operative samples collected 
while the patient was considered disease-free according to their most recent clinical and radiological 
evaluation. Red dots represent samples collected after the first radiological manifestation of recurrent 
disease and before any second curative therapy. Purple dots represent samples that were collected pre-
operatively. Panel B, Heat-map visualization of longitudinal urinary steroid profile results in five 
representative patients who developed recurrent disease during follow-up. Arrows indicate the time 
of the first radiological manifestation of recurrent disease (Rec) and surgery for recurrence (Sx). Steroid 
numbers correspond to steroid metabolites as tabulated in Table 1.  
Fig. 3: Comparison of pre-operative (baseline) and post-recurrence samples (13 patients with a 
total of 15 recurrences). Panel A, Overlap between baseline urine steroid profile and the profile of the 
first post-recurrence sample provided by the same patient, when considering the 6 most elevated steroid 
metabolites in each sample. Steroid values were normalized to the upper limit of the reference range of 
the corresponding steroid metabolite in sex-matched healthy controls. Panel B, Frequency of inclusion of 
each   e  i   e a  li e i   he ‘     ’      ele a e    e  i   i  a  e  . The presented panel consists of 
the 8 steroid biomarkers previously described a   a       he “ ali  a     e  i   i  e   i  ”  ia     ic     
ACC (15). 
Fig. 4: Assessment of longitudinally collected urine steroid profiling results by three expert 
clinicians (C1-3).  Panels A+B, Clinician assessment in the 32 patients who developed disease 
recurrence, grouped according to whether they had provided pre-operative urine samples (N=13) or not 
(N=19) (A) or whether they had adjuvant mitotane treatment at the time of recurrence (N=12) or not 
(N=20) (B). Panel C, Clinician assessment of urine profiles from 31 patients who remained disease-free 
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for at least three years post-operatively and provided at least two post-operative samples.  Panel D, Time 
interval between the detection of recurrent ACC by imaging and the earliest detection by clinician 
assessment of urine steroid profiles. Each point corresponds to a single urine sample; no patient is 
represented by more than one sample. Negative values indicate that biochemical detection preceded 
radiological detection.    
Fig. 5: Machine learning-based analysis of the urine steroid profile results. Panel A, Receiver 
operating characteristics (ROC) curve analysis of the performance of Random Forest classification in 
distinguishing post-recurrence samples from samples provided by non-recurred patients. The performance 
of the three clinician assessors (C1, C2 and C3) has also been plotted for comparison.  Steroid numbers 
correspond to Table 1. Panel B, Random Forest assessment of the relative importance of the 19 steroid 
metabolites in distinguishing post-recurrence samples (N=32) from post-operative samples provided by 
non-recurred patients (N=39), quantifying the significance of each single steroid marker for the detection 
of ACC recurrence, with all significances adding up to the sum of 1. 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/clinem
/dgz141/5609065 by U
niversity of Birm
ingham
 user on 21 N
ovem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
 
 23 
Figure 1 
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Figure 2 
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Figure 4 
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Figure 5 
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Table 1: Urinary steroid metabolites quantified by gas chromatography-mass spectrometry and their 
corresponding steroids of origin. These 19 steroids include 8 steroid metabolites (indicated by *) 
  e i   ly  e c i e  a  c     e        he “ ali  a     e  i   i  e   i  ”  ia     ic     a  e  c   ical 
carcinoma (ACC) upon analysis of 24-h urines from patients with benign and malignant adrenocortical 
masses (15). 
 
No Steroid Metabolite Metabolite of 
 Androgen and androgen precursor metabolites 
1 Androsterone (An)  a      e e i  e,  e     e   e, 5α-dihydrotestosterone 
2 Etiocholanolone (Et) *  androstenedione, testosterone 
3   β-hy    ya      e   e (  β-OHAn)  a      e e i  e,   β-hydroxyandrostenedione 
4 Dehydroepiandrosterone (DHEA)  DHEA, DHEAS 
5 16-hydroxy-DHEA (  α-DHEA)  DHEA, DHEAS 
6 5-pregnenetriol (5-PT) *  17-hydroxypregnenolone 
7 5-pregnenediol (5-PD) *  Pregnenolone 
 
Mineralocorticoid and mineralocorticoid precursor metabolites 
8 Tetrahydro-11-deoxycorticosterone (THA)  corticosterone, 11-dehydrocorticosterone 
9 
 5-tetrahydro-11- e  yc   ic   e   e (5α-
ΤΗΑ) * 
 corticosterone, 11-dehydrocorticosterone 
10  Tetraydrocorticosterone (THB)  Corticosterone 
11  5α- e  ahy   c   ic   e   e (5α-THB)  Corticosterone 
12  3,5-tetrahydroaldosterone (THALDO)     Aldosterone 
13  Tetrahydrodeoxycorticosterone (THDOC) *  11-deoxycorticosterone 
 
 Glucocorticoid precursor metabolites 
14  Pregnanediol (PD) *  Progesterone 
15 
 3,5-17-hydroxypregnanolone (3,5-
17HP)    
 17-hydroxyprogesterone 
16  17-hydroxypregnanolone (17HP)  17-hydroxyprogesterone 
17  Pregnanetriol (PT) *  17-hydroxyprogesterone 
18  Pregnanetriolone (PTONE)  21-deoxycortisol 
19  Tetrahydro-11-deoxycortisol (THS) *  11-deoxycortisol 
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Table 2: De    a hic a   cli ical cha ac e i  ic      he ‘ ec   e ce’ c h    ( a ie     i h  i ea e 
recurrence and at least one post- ec   e ce   i e; N=32) a    he ‘ ec   e ce-  ee’ c h    ( a ie     i ea e 
free after 3 years of follow-up; N=39). Where data are not available for the full cohort, number of 
patients with available data is provided as denominator.  N: number, IQR: interquartile range, N/A: not 
applicable. 
 Recurred patients (N=32) Recurrence-free patients 
(N=39) 
 
Post-operative 24-h urine 
samples collected  total N 
 
237 
 
216 
Age (years) 
Median (range) 
52 (22-80) 56 (24-75) 
Male patients  
N (%) 
7 (22%) 17 (44%) 
 
Primary tumor size (mm)        
median (IQR) 
 
92 (70-118) 
 
80 (66-140) 
Evidence of biochemical 
hormone excess on routine 
biochemistry N/total N (%) 
 
23/31 (74%) 16/33 (48%) 
Type of hormone excess on 
routine biochemistry 
N 
Glucocorticoids (GC) only:   6 
Androgens only:  2 
Mineralocorticoids (MC) only: 0 
Precursor steroids only: 0 
GC + Androgens:  12 
MC + GC or Androgens: 3 
GC only:   5 
Androgens only:  3 
MC only: 1 
Precursor steroids only: 1   
GC +Androgens:  4 
MC + GCs or Androgens: 2 
Clinically overt Cushing’s 
syndrome  N/total N (%) 
 
16/31  (52%) 5/38 (13%) 
Histology primary tumor:  
Ki67 (%) median (IQR) 
 
10 (7-26) 8 (5-15) 
Histology primary tumor: 
Weiss score (0-9) median (IQR) 
 
5 (4-7) 5 (3-7) 
Adjuvant mitotane treatment  
N (%) 
 
20 (63%) 27 (69%) 
Duration of follow up (months) 
median (IQR) 
 
27 (18-44) 51 (41-65)  
Time to recurrence, (months) 
median (IQR) 
 
15 (10-25)  N/A 
Maximum recurrent lesion size 
(mm)  median (range) 
 
11 (3-45) N/A 
Number of organs involved in 
recurrence 
1 (N=27); 2 (N=6); 3 (N=3) N/A 
Location of recurrences Lung (N=22); Liver (N=10); 
Lymph nodes (N=5); 
Local recurrence (N=4); 
Bone, spleen, omentum, pleura 
N/A 
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(each N=1) 
 
Table 3: Quantitation of the increases in the eight urine steroid metabolites previously described as part 
    he “ ali  a     e  i   i  e   i  ”  ia     ic     A   (15), expressed as fold change in comparison to 
the upper limit of normal (ULN) referring to a healthy adult control cohort. We compared steroid 
excretion in the pre-operative samples collected with the primary tumor in situ to the first urine samples 
collected after radiological recurrence detection (= 1
st
 post-recurrence sample)  in the 13 patients with 
ACC recurrence who provided both pre- and post-operative urine samples.  
Steroids Pre-operative sample 
Fold ULN 
Median (5
th
-95
th
 centile) 
 
1
st
 post-recurrence sample 
Fold ULN 
Median (5
th
-95
th 
centile) 
 
 
THS 6.57 (0.83-41.2) 1.54 (0.35-14.50) 
5-PD 3.80 (0.79-39.4) 0.43 (0.08-4.00) 
PD 2.93 (0.51-8.80) 0.16 (0.03-1.10) 
PT 1.70 (0.51-10.50) 0.22 (0.08-1.00) 
5-PT 1.69 (0.53-20.00) 0.17 (0.04-4.40) 
THDOC 1.39 (0.15-2.90) 0.21 (0.11-1.50) 
Etio 1.19 (0.12-3.30) 0.09 (0.02-1.00) 
5α-THA 0.47 (0.10-1.00) 0.33 (0.09-0.51) 
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